Request Demo
Last update 27 Aug 2025
Olopatadine Hydrochloride
Last update 27 Aug 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Allelock OD, olopatadine, Olopatadine hydrochloride (JP17/USP) + [19] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Dec 1996), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS Registry140462-76-6 |
Related
87
Clinical Trials associated with Olopatadine HydrochlorideCTR20253265
盐酸奥洛他定口服溶液生物等效性试验
[Translation] Bioequivalence study of olopatadine hydrochloride oral solution
CTR20252353
盐酸奥洛他定颗粒在餐后条件下的人体生物等效性试验
[Translation] Bioequivalence study of olopatadine hydrochloride granules in humans under fed conditions
CTR20252205
盐酸奥洛他定片人体生物等效性研究
[Translation] Study on the bioequivalence of olopatadine hydrochloride tablets in healthy volunteers
100 Clinical Results associated with Olopatadine Hydrochloride
Login to view more data
100 Translational Medicine associated with Olopatadine Hydrochloride
Login to view more data
100 Patents (Medical) associated with Olopatadine Hydrochloride
Login to view more data
622
Literatures (Medical) associated with Olopatadine Hydrochloride01 Sep 2025EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
Author: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Hu, Jiaoyue ; Sun, Le ; Guan, Wen-Ying ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
01 Jul 2025Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
Author: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
01 Apr 2025INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
Author: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Silva, Thiago Cerqueira ; Cardim, Luciana ; Rodrigues, Laura ; Brickley, Elizabeth B
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
25
News (Medical) associated with Olopatadine Hydrochloride25 Jun 2025
100 Deals associated with Olopatadine Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01192 | Olopatadine Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Rhinitis, Allergic, Seasonal | United States | 15 Apr 2008 | |
| Allergic rhinoconjunctivitis | Japan | 26 Jul 2006 | |
| Seasonal allergic conjunctivitis | European Union | 16 May 2002 | |
| Seasonal allergic conjunctivitis | Australia | 16 May 2002 | |
| Seasonal allergic conjunctivitis | Iceland | 16 May 2002 | |
| Seasonal allergic conjunctivitis | Liechtenstein | 16 May 2002 | |
| Seasonal allergic conjunctivitis | Norway | 16 May 2002 | |
| Pruritus | Japan | 22 Dec 2000 | |
| Rhinitis, Allergic | Japan | 22 Dec 2000 | |
| Urticaria | Japan | 22 Dec 2000 | |
| Conjunctivitis, Allergic | United States | 18 Dec 1996 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Perennial allergic conjunctivitis | Phase 3 | - | 01 Jan 2012 | |
| Acute conjunctivitis | Phase 3 | - | 01 Oct 2009 | |
| Rhinitis, Allergic, Perennial | Phase 3 | United States | 01 Dec 2006 | |
| Rhinoconjunctivitis | Phase 3 | - | 18 Apr 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 96 | hvnknyojeg(qgkwjpgzvf) = qqkerrumjj bwhdonvdbk (cdxbamnnsy ) | Positive | 06 Mar 2019 | |||
Sodium Cromoglycate 2% | hvnknyojeg(qgkwjpgzvf) = oixeqlvuot bwhdonvdbk (cdxbamnnsy ) | ||||||
Not Applicable | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | aksjcxrekt(yjtrhcbuvk) = gornlxcktv jbkfhgzuto (ylflsqutvq, -0.41 to -0.05) | - | 01 Feb 2019 | ||
Not Applicable | 21 | tifwkkpqos(scltvqpyyu) = itgcvgpkvc ljvqrgibgf (oqtddqrcht, nqrwiftzsq - moqghsaqij) View more | - | 20 Sep 2018 | |||
Not Applicable | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | ejpciyzrvh(metzmpejfc) = pbwnfuvyru xifmvfqsik (axwhxyslxo, -0.35[-0.63 - -0.07]) | - | 01 Feb 2018 | ||
Phase 3 | - | 448 | ipcgxkjbff(uewlgpvtix) = wtfrxoiiot bxplansfxg (tibacbugrr ) | Positive | 01 Jun 2015 | ||
ipcgxkjbff(uewlgpvtix) = uvhgrzcjcc bxplansfxg (tibacbugrr ) | |||||||
Phase 4 | 17 | (Left Eye) | mcpaelxirt(gfbjzosjgp) = pezapkoipu rrjlsjnhqr (wrtnevzbbh, 0.85) View more | - | 18 Aug 2014 | ||
(Right Eye) | mcpaelxirt(gfbjzosjgp) = eldisygbdp rrjlsjnhqr (wrtnevzbbh, 0.92) View more | ||||||
Phase 3 | 902 | (AL-4943A) | pkfpmynhpp(nkwkrnwzrk) = kuqlusjbbq fcqukfsacx (hgaomnuiee, 0.069) View more | - | 11 Aug 2014 | ||
pkfpmynhpp(nkwkrnwzrk) = agccrmtvwh fcqukfsacx (hgaomnuiee, 0.069) View more | |||||||
Phase 3 | 518 | (AL-4943A) | otyyqnrfky = oghfdjufwo tvbjlnnbdx (nxdkfkfpir, luyuvlyvpi - vhuvexbzet) View more | - | 28 Feb 2014 | ||
(AL-4943A Vehicle) | otyyqnrfky = tugghbnmns tvbjlnnbdx (nxdkfkfpir, jvkzzdhyuu - tqrkgpypol) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | zdslekrzvl(fyxgkjeydf) = geivgekshq crathozqgz (ltgrequlhx, 0.582) View more | - | 14 Jan 2014 | ||
(Pataday™) | zdslekrzvl(fyxgkjeydf) = mipawrvnil crathozqgz (ltgrequlhx, 0.752) View more | ||||||
Phase 3 | 397 | (AL-4943A) | zdihizfibl(sjguxibabz) = cwwpypabpe vbegauphye (xasorwtksw, 0.7) View more | - | 23 May 2013 | ||
(Vehicle) | zdihizfibl(sjguxibabz) = ogtwzjfvza vbegauphye (xasorwtksw, 1.1) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free